GlaxoSmithKline pleads guilty to health fraud (Update)

In this Nov. 5, 2008 file photo passers-by walk past the American headquarters of British drug maker GlaxoSmithKline PLC, in Philadelphia. A federal judge in Boston approved Thursday, July 5, 2012 to an agreement by British drugmaker GlaxoSmithKline to pay $3 billion for criminal and civil violations involving 10 drugs, marking the largest health care fraud settlement in U.S. history. (AP Photo/Matt Rourke, File)

(AP) — A U.S. judge on Thursday approved an agreement by British drugmaker GlaxoSmithKline to pay $3 billion for criminal and civil violations involving 10 drugs, the largest health care fraud settlement in U.S. history.

The amount of money involved led U.S. District Judge Rya Zobel to remark in court that she was having trouble keeping track of the numbers.

GlaxoSmithKline pleaded guilty to promoting the popular antidepressants Paxil and Wellbutrin for unapproved uses.

Government officials said in the original complaint that the company promoted Paxil as safe for children and adolescents, even though the U.S. Food and Drug Administration hadn't approved it for those patients and the company's clinical trials raised concerns about an increased suicide risk.

Prosecutors had charged that the drugmaker promoted Wellbutrin for unapproved uses that included treating attention deficit disorder, bipolar disorder, obesity, sexual dysfunction and anxiety when it wasn't shown to be safe and effective for those uses.

In this June 30, 2010 file photo, a pharmacist holds a bottle of the drug Avandia at Maximart Pharmacy in Palo Alto, Calif. GlaxoSmithKline on Thursday, July 5, 2012, in U.S. District Court in Boston pleaded guilty to failing to report to the government some safety problems with diabetes drug Avandia. The company also pleaded guilty to promoting popular antidepressants Paxil and Wellbutrin for unapproved uses. (AP Photo/Paul Sakuma, file)

The company also admitted that it failed to report to the government some safety problems with Avandia. In 2010, the diabetes drug was restricted in the U.S. and banned in Europe after it was found to sharply increase the risks of heart attacks and congestive heart failure.

Defense lawyer Geoffrey Hobart and Assistant U.S. Attorney Sara Bloom declined to comment immediately following Thursday's hearing.

A GlaxoSmithKline spokesman referred later to comments CEO Sir Andrew Witty made Monday, including that the company has learned "from the mistakes that were made."

When the government announced the settlement Monday, U.S. Deputy Attorney General James M. Cole called it historic, saying it sent a clear warning to any company that chooses to break the law.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

GlaxoSmithKline to pay $3 billion for health fraud

Jul 02, 2012

(AP) — GlaxoSmithKline LLC will pay $3 billion and plead guilty to promoting two popular drugs for unapproved uses and to failing to disclose important safety information on a third in the largest health ...

Glaxo defends handling of Avandia heart risks

Feb 24, 2010

(AP) -- GlaxoSmithKline said Wednesday a Senate report criticizing its handling of heart risks with its diabetes drug Avandia "mischaracterizes and distorts" the company's record.

Recommended for you

User comments